Japan's Teijin Pharma Limited has announced that Feburic indicated for the treatment of hyperuricemia, with or without gout, has been approved by Japan's Ministry of Health, Labour and Welfare as an indication for hyperuricemia caused by cancer chemotherapy.

The press release said that Febuxostat, currently sold in 57 countries, is expected to be made available in 117 markets in regions including North America, Europe and Asia. It is currently marketed as Adenuric in Europe, where it was approved in April 2015 for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of tumor lysis syndrome (TLS).

Going forward, Teijin Pharma aims to expand febuxostat's global development to enhance the treatment of hyperuricemia and improve the quality of life for patients.
Febuxostat, a highly potent oral drug taken once daily, is indicated for the treatment of hyperuricemia with or without gout and available in 10mg, 20mg, and 40mg tablets under the brand name of Feburic in Japan. The normal maintenance dose is 40mg taken orally once daily and the maximum dose is 60mg. The newly approved indication in Japan for hyperuricemia caused by cancer chemotherapy is 60mg taken orally once daily.